Given that dementia, dysautonomia, and atypical features are uncommon and patients frequently develop fluctuations and dyskinesia, PRKN-PD patients are ideal candidates for DBS and infusion therapies (Kasten et al., 2018; Guadagnolo et al., 2021; Salles et al., 2021; Jia et al., 2022; Dulski et al., forthcoming). Here, PRKN is linked to Parkinson disease.